BR112023020685A2 - Acopladores de cd70 baseados em darpin - Google Patents

Acopladores de cd70 baseados em darpin

Info

Publication number
BR112023020685A2
BR112023020685A2 BR112023020685A BR112023020685A BR112023020685A2 BR 112023020685 A2 BR112023020685 A2 BR 112023020685A2 BR 112023020685 A BR112023020685 A BR 112023020685A BR 112023020685 A BR112023020685 A BR 112023020685A BR 112023020685 A2 BR112023020685 A2 BR 112023020685A2
Authority
BR
Brazil
Prior art keywords
nucleic acids
binding proteins
darpin
human
pharmaceutical compositions
Prior art date
Application number
BR112023020685A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernd Schlereth
Christian Reichen
Nina Reschke
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112023020685A2 publication Critical patent/BR112023020685A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Lock And Its Accessories (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023020685A 2021-04-09 2022-04-07 Acopladores de cd70 baseados em darpin BR112023020685A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US202163265181P 2021-12-09 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (1)

Publication Number Publication Date
BR112023020685A2 true BR112023020685A2 (pt) 2023-12-12

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020685A BR112023020685A2 (pt) 2021-04-09 2022-04-07 Acopladores de cd70 baseados em darpin

Country Status (9)

Country Link
US (1) US20250074994A1 (https=)
EP (1) EP4319883A1 (https=)
JP (1) JP2024513559A (https=)
KR (1) KR20230169182A (https=)
AU (1) AU2022252985A1 (https=)
BR (1) BR112023020685A2 (https=)
CA (1) CA3214020A1 (https=)
MX (1) MX2023011978A (https=)
WO (1) WO2022215032A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4724460A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
PL2643349T3 (pl) * 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
AU2014317009A1 (en) * 2013-09-05 2016-03-10 Aduro Biotech Holdings, Europe B.V. CD70-binding peptides and method, process and use relating thereto
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
PE20210708A1 (es) * 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
KR20260046525A (ko) * 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Also Published As

Publication number Publication date
KR20230169182A (ko) 2023-12-15
JP2024513559A (ja) 2024-03-26
MX2023011978A (es) 2023-11-17
CA3214020A1 (en) 2022-10-13
WO2022215032A1 (en) 2022-10-13
AU2022252985A1 (en) 2023-11-16
US20250074994A1 (en) 2025-03-06
EP4319883A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
BR112023020685A2 (pt) Acopladores de cd70 baseados em darpin
BR112022023049A2 (pt) Proteínas multiespecíficas
BR112023018293A2 (pt) Acopladores de célula t multiespecíficos à base de darpin
BR112021024231A2 (pt) Proteínas de ligação fap recombinantes e uso da mesma
BR112022011456A2 (pt) Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
Au et al. TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
CO2022016595A2 (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
Kwak et al. Reactive oxygen species induce Cys106-mediated anti-parallel HMGB1 dimerization that protects against DNA damage
Nakao et al. Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway
TW201606083A (zh) 製備誘導多能幹細胞之方法及其應用
CO2024012037A2 (es) Anticuerpos multiespecíficos y usos de estos
Zhu et al. Chromatin restoration following nucleotide excision repair involves the incorporation of ubiquitinated H2A at damaged genomic sites
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
Prusinski Fernung et al. A preliminary study: human fibroid Stro-1+/CD44+ stem cells isolated from uterine fibroids demonstrate decreased DNA repair and genomic integrity compared to adjacent myometrial Stro-1+/CD44+ cells
Behera et al. Abrus precatorius agglutinin-derived peptides induce ROS-dependent mitochondrial apoptosis through JNK and Akt/P38/P53 pathways in HeLa cells
Neary et al. Calcium-activated, phospholipid-dependent protein kinase and protein substrates in primary cultures of astrocytes
WO2021116470A3 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
BR112022018491A2 (pt) Marcadores de superfície celular recombinante
Nakajima et al. Immunohistochemical demonstration of 14‐3‐3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage
ECSP22075305A (es) Variantes de alfa-galactosidasa humana
MX2021015501A (es) Anticuerpos y metodos de uso.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]